$CSTL
CASTLE BIOSCIENCES INC Stock $cstl

$cstl Overview Financials Valuation SEC Filings Company Website

2021 Q2 Form 10-Q Financial Statement

#000144736221000199 Filed on August 09, 2021

Income Statement

Concept	2021 Q2	2020 Q2
Revenue	$22.76M	$12.72M
YoY Change	78.99%	18.4%
Cost Of Revenue	$3.697M	$2.146M
YoY Change	72.27%	7.68%
Gross Profit	$19.06M	$10.57M
YoY Change	80.35%	20.84%
Gross Profit Margin	83.76%	83.12%
Selling, General & Admin	$20.82M	$10.39M
YoY Change	100.37%	52.35%
% of Gross Profit	109.24%	98.33%
Research & Development	$6.793M	$2.704M
YoY Change	151.22%	105.32%
% of Gross Profit	35.64%	25.58%
Depreciation & Amortization	$378.0K	$102.0K
YoY Change	270.59%	18.6%
% of Gross Profit	1.98%	0.97%
Operating Expenses	$27.62M	$13.10M
YoY Change	110.87%	60.92%
Operating Profit	-$8.810M	-$645.0K
YoY Change	1265.89%	-206.09%
Interest Expense	$0.00	$769.0K
YoY Change	-100.0%	-54.58%
% of Operating Profit
Other Income/Expense, Net		$0.00
YoY Change		-100.0%
Pretax Income	-$8.786M	-$1.380M
YoY Change	536.67%	8.66%
Income Tax	$5.000K	$0.00
% Of Pretax Income
Net Earnings	-$8.791M	-$1.376M
YoY Change	538.88%	8.43%
Net Earnings / Revenue	-38.63%	-10.82%
Basic Earnings Per Share	-$0.35	-$0.08
Diluted Earnings Per Share	-$0.35	-$0.08
COMMON SHARES
Basic Shares Outstanding	25.09M shares	17.54M shares
Diluted Shares Outstanding	25.09M shares	17.54M shares

Balance Sheet

Concept	2021 Q2	2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$368.3M	$179.8M
YoY Change	104.86%	927.43%
Cash & Equivalents	$368.3M	$179.8M
Short-Term Investments
Other Short-Term Assets	$3.419M	$1.700M
YoY Change	101.12%	112.5%
Inventory	$2.124M	$1.667M
Prepaid Expenses
Receivables	$17.82M	$12.53M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$391.7M	$195.7M
YoY Change	100.18%	585.97%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.092M	$5.024M
YoY Change	61.07%	188.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.631M	$199.0K
YoY Change	719.6%	-89.03%
Total Long-Term Assets	$43.83M	$5.875M
YoY Change	646.11%	21.82%
TOTAL ASSETS
Total Short-Term Assets	$391.7M	$195.7M
Total Long-Term Assets	$43.83M	$5.875M
Total Assets	$435.5M	$201.5M
YoY Change	116.1%	504.39%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.368M	$2.495M
YoY Change	-45.17%	19.67%
Accrued Expenses	$11.10M	$7.300M
YoY Change	52.04%	65.91%
Deferred Revenue	$6.177M	$8.350M
YoY Change	-26.02%
Short-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due		$10.00M
YoY Change		1100.0%
Total Short-Term Liabilities	$18.65M	$28.24M
YoY Change	-33.95%	140.45%
LONG-TERM LIABILITIES
Long-Term Debt	$963.0K	$14.74M
YoY Change	-93.47%	-38.22%
Other Long-Term Liabilities	$0.00	$900.0K
YoY Change	-100.0%	-30.77%
Total Long-Term Liabilities	$963.0K	$14.74M
YoY Change	-93.47%	-38.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.65M	$28.24M
Total Long-Term Liabilities	$963.0K	$14.74M
Total Liabilities	$19.62M	$43.92M
YoY Change	-55.34%	18.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$75.57M	-$53.02M
YoY Change	42.53%	-11.78%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$415.9M	$157.6M
YoY Change
Total Liabilities & Shareholders Equity	$435.5M	$201.5M
YoY Change	116.1%	504.39%

Cashflow Statement

Concept	2021 Q2	2020 Q2
OPERATING ACTIVITIES
Net Income	-$8.791M	-$1.376M
YoY Change	538.88%	8.43%
Depreciation, Depletion And Amortization	$378.0K	$102.0K
YoY Change	270.59%	18.6%
Cash From Operating Activities	-$6.439M	$13.50M
YoY Change	-147.7%	2712.5%
INVESTING ACTIVITIES
Capital Expenditures	-$913.0K	-$1.760M
YoY Change	-48.12%	877.78%
Acquisitions
YoY Change
Other Investing Activities	-$33.18M
YoY Change
Cash From Investing Activities	-$34.10M	-$1.760M
YoY Change	1837.22%	877.78%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.891M	69.36M
YoY Change	-97.27%	7358.06%
NET CHANGE
Cash From Operating Activities	-6.439M	13.50M
Cash From Investing Activities	-34.10M	-1.760M
Cash From Financing Activities	1.891M	69.36M
Net Change In Cash	-38.64M	81.10M
YoY Change	-147.65%	6493.5%
FREE CASH FLOW
Cash From Operating Activities	-$6.439M	$13.50M
Capital Expenditures	-$913.0K	-$1.760M
Free Cash Flow	-$5.526M	$15.26M
YoY Change	-136.21%	2212.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001447362
	dei	Document Period End Date DocumentPeriodEndDate	2021-06-30
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38984
	dei	Entity Registrant Name EntityRegistrantName	CASTLE BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	77-0701774
	dei	Entity Address Address Line1 EntityAddressAddressLine1	505 S. Friendswood Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 401
	dei	Entity Address City Or Town EntityAddressCityOrTown	Friendswood
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77546
CY2020Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	7175000	USD
	dei	City Area Code CityAreaCode	866
	dei	Local Phone Number LocalPhoneNumber	788-9007
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value per share
	dei	Trading Symbol TradingSymbol	CSTL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25167365	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	368339000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	409852000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17817000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12759000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	2124000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2098000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	2217000	USD
CY2021Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3419000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4766000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	391699000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	429594000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1313000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Noncurrent AccountsReceivableNetNoncurrent	1096000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8092000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7102000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32798000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	0	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1631000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1536000	USD
CY2021Q2	us-gaap	Assets Assets	435533000	USD
CY2020Q4	us-gaap	Assets Assets	439328000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1368000	USD
CY2021Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8584000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9108000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6177000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6615000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2525000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3055000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	18654000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20876000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1735000	USD
CY2021Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	963000	USD
CY2020Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1026000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	19617000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	23637000	USD
CY2021Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q2	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2020Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25164053	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25164053	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	24812487	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	24812487	shares
CY2021Q2	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	25000	USD
CY2020Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	25000	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	491458000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	478162000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-75567000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-62496000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	415916000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	415691000	USD
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	435533000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	439328000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22758000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12715000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	45571000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	38983000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21470000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30133000	USD
CY2021Q2	us-gaap	Cost Of Revenue CostOfRevenue	3697000	USD
CY2020Q2	us-gaap	Cost Of Revenue CostOfRevenue	2146000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	6725000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	4537000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6793000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2704000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12701000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5617000	USD
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20822000	USD
CY2020Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	10392000	USD
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	256000	USD
CY2020Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	256000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	0	USD
CY2021Q2	us-gaap	Other Operating Income OtherOperatingIncome	0	USD
CY2020Q2	us-gaap	Other Operating Income OtherOperatingIncome	1882000	USD
	us-gaap	Other Operating Income OtherOperatingIncome	0	USD
	us-gaap	Other Operating Income OtherOperatingIncome	1882000	USD
CY2021Q2	cstl	Operating Expenses Net Of Other Operating Income OperatingExpensesNetOfOtherOperatingIncome	31568000	USD
CY2020Q2	cstl	Operating Expenses Net Of Other Operating Income OperatingExpensesNetOfOtherOperatingIncome	13360000	USD
	cstl	Operating Expenses Net Of Other Operating Income OperatingExpensesNetOfOtherOperatingIncome	58665000	USD
	cstl	Operating Expenses Net Of Other Operating Income OperatingExpensesNetOfOtherOperatingIncome	29742000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-8810000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-645000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13094000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	391000	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	24000	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	38000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	28000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	336000	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	0	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	769000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	1533000	USD
CY2021Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-8786000	USD
CY2020Q2	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-1376000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-13066000	USD
	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-806000	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8791000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8791000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1376000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1376000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13071000	USD
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13071000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-806000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-806000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.52
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
CY2020Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.52
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25091000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17544000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	25002000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17458000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25091000	shares
CY2020Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17544000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	25002000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17458000	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	85113000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1577000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	71000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	603000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	570000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	87934000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1653000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	330000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	69081000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-1376000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	157622000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	415691000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4913000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	991000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1233000	USD
CY2021Q1	cstl	Adjustments To Additional Paid In Capital Stock Issuance Costs Adjustments Increase AdjustmentsToAdditionalPaidInCapitalStockIssuanceCostsAdjustmentsIncrease	39000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4280000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	418587000	USD
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	4766000	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1354000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8791000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	415916000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13071000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-806000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	867000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	193000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	9679000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3230000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	452000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2337000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1347000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-69000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5275000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-234000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-223000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	430000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	95000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	62000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-683000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	444000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-523000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1127000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2173000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	8350000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-306000	USD
	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	263000	USD
	cstl	Increase Decreasein Deferred Lease Liability IncreaseDecreaseinDeferredLeaseLiability	-128000	USD
	cstl	Increase Decreasein Deferred Lease Liability IncreaseDecreaseinDeferredLeaseLiability	172000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10069000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	13250000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1663000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2256000	USD
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	33184000	USD
	us-gaap	Payments To Acquire Other Productive Assets PaymentsToAcquireOtherProductiveAssets	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34845000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2256000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	69530000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	336000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	714000	USD
	cstl	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
	cstl	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	451000	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	0	USD
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	833000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2345000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	400000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	1392000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	823000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3401000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	69920000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41513000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	80914000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	409852000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	98845000	USD
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	368339000	USD
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	179759000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	194000	USD
	cstl	Property And Equipment Acquired With Tenant Improvement Allowance PropertyAndEquipmentAcquiredWithTenantImprovementAllowance	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of long-lived assets, the valuation of acquired intangible assets and contingent liabilities. We base these estimates on historical and anticipated results, trends, and various other assumptions that we believe are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. We have considered the potential impact of the COVID-19 pandemic on our estimates and assumptions. The extent to which the COVID-19 pandemic may impact our estimates in future periods is uncertain and subject to change.
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2021Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	USD
CY2020Q2	cstl	Other Operating Income Loss Cares Act OtherOperatingIncomeLossCARESAct	1900000	USD
	cstl	Other Operating Income Loss Cares Act OtherOperatingIncomeLossCARESAct	1900000	USD
CY2021Q2	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	5742000	USD
	cstl	Contract With Customer Customer Payment Terms ContractWithCustomerCustomerPaymentTerms	P30D
CY2021Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	-166000	USD
CY2020Q2	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	2291000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	5092000	USD
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	1048000	USD
CY2020Q2	cstl	Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Payment Received CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramPaymentReceived	8300000	USD
CY2021Q2	cstl	Centers For Medicare And Medicaid Services Accelerated And Advanced Payment Program Recoupment Of Advanced Payment CentersForMedicareAndMedicaidServicesAcceleratedAndAdvancedPaymentProgramRecoupmentOfAdvancedPayment	2173000	USD
	cstl	Revenue From Contract With Customer Revenue Not Yet Recognized Number Of Claims In Adjudication Process RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess	2698	claim
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3430000	shares
CY2020Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2870000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3483000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2855000	shares
CY2021Q2	us-gaap	Asset Acquisition Consideration Transferred Transaction Cost AssetAcquisitionConsiderationTransferredTransactionCost	684000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10340000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8756000	USD
CY2021Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2248000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1654000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8092000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7102000	USD
CY2021Q2	us-gaap	Depreciation Depreciation	378000	USD
CY2020Q2	us-gaap	Depreciation Depreciation	102000	USD
	us-gaap	Depreciation Depreciation	611000	USD
	us-gaap	Depreciation Depreciation	193000	USD
	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P11Y10M24D
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1891000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1388000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2753000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2753000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2761000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2753000	USD
CY2021Q2	cstl	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	20390000	USD
CY2021Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	32798000	USD
CY2021Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1054000	USD
CY2021Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	692000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	536000	USD
CY2021Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	277000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	276000	USD
CY2021Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	214000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	151000	USD
CY2021Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	10000	USD
CY2020Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	62000	USD
CY2021Q2	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	278000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	139000	USD
CY2021Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2525000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	3055000	USD
CY2020Q2	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	37.00
	cstl	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	451000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3369502	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	28.11
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	149837	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	69.02
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	282685	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.22
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	106831	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	31.16
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3129823	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M17D
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	130366000	USD
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	932684	shares
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	15.66
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y5M23D
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	53790000	USD
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	39203	shares
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4766000	USD
CY2020Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1653000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9679000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3230000	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	55235000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y1M6D

Files In Submission

Name	View Source	Status
0001447362-21-000199-index-headers.html	Edgar Link	pending
0001447362-21-000199-index.html	Edgar Link	pending
0001447362-21-000199.txt	Edgar Link	pending
0001447362-21-000199-xbrl.zip	Edgar Link	pending
cstl-20210630.htm	Edgar Link	pending
cstl-20210630.xsd	Edgar Link	pending
cstl-20210630_cal.xml	Edgar Link	unprocessable
cstl-20210630_def.xml	Edgar Link	unprocessable
cstl-20210630_htm.xml	Edgar Link	completed
cstl-20210630_lab.xml	Edgar Link	unprocessable
cstl-20210630_pre.xml	Edgar Link	unprocessable
exhibit101-consultingagree.htm	Edgar Link	pending
exhibit311-q22021.htm	Edgar Link	pending
exhibit312-q22021.htm	Edgar Link	pending
exhibit321-q22021.htm	Edgar Link	pending
exhibit322-q22021.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSTL
CASTLE BIOSCIENCES INC Stock $cstl

2021 Q2 Form 10-Q Financial Statement

#000144736221000199 Filed on August 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL CASTLE BIOSCIENCES INC Stock $cstl

2021 Q2 Form 10-Q Financial Statement

#000144736221000199 Filed on August 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSTL
CASTLE BIOSCIENCES INC Stock $cstl